BACKGROUND/AIMS: Plasma fluorescent oxidation products (FLOP) constitute a stable and easily measured biomarker of cumulative oxidative stress. However, their association with chronic kidney disease (CKD) has not been studied. METHODS: We examined the association of FLOP and CKD in 201 CKD patients and 201 controls without CKD from the community. CKD was defined as an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m(2) or the presence of albuminuria. RESULTS: Adjusted median (interquartile range) FLOP levels were significantly higher in patients with CKD than in controls [FLOP1 (lipid oxidation products): 215.2 (181.3-268.7) vs. 156.6 (139.6-177.3) fluorescent intensity units/ml, p < 0.0001; FLOP2 (DNA oxidation products): 534.8 (379.3-842.4) vs. 269.9 (232.4-410.5) fluorescent intensity units/ml, p < 0.0001; FLOP3 (protein and phospholipid oxidation products): 51.4 (44.4-66.0) vs. 45.2 (38.3-51.7) fluorescent intensity units/ml, p = 0.002]. Compared with those with a FLOP level below the 75th percentile, participants with a FLOP level above the 75th percentile had increased odds of CKD after adjustment for covariables (FLOP1: odds ratio 13.1, 95% confidence interval 6.2-27.6; FLOP2: odds ratio 5.7, 95% confidence interval 2.9-11.1; FLOP3: odds ratio 2.4, 95% confidence interval 1.2-4.7). Levels of FLOP1, FLOP2 and FLOP3 were related to eGFR (p < 0.0001 for all) and log-transformed urine albumin (p < 0.005 for all) in multivariable-adjusted linear regression models. CONCLUSION: These data indicate that an elevated FLOP level is associated with CKD status and severity. Future studies are warranted to elucidate its role in the development and progression of CKD.
BACKGROUND/AIMS: Plasma fluorescent oxidation products (FLOP) constitute a stable and easily measured biomarker of cumulative oxidative stress. However, their association with chronic kidney disease (CKD) has not been studied. METHODS: We examined the association of FLOP and CKD in 201 CKD patients and 201 controls without CKD from the community. CKD was defined as an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m(2) or the presence of albuminuria. RESULTS: Adjusted median (interquartile range) FLOP levels were significantly higher in patients with CKD than in controls [FLOP1 (lipid oxidation products): 215.2 (181.3-268.7) vs. 156.6 (139.6-177.3) fluorescent intensity units/ml, p < 0.0001; FLOP2 (DNA oxidation products): 534.8 (379.3-842.4) vs. 269.9 (232.4-410.5) fluorescent intensity units/ml, p < 0.0001; FLOP3 (protein and phospholipid oxidation products): 51.4 (44.4-66.0) vs. 45.2 (38.3-51.7) fluorescent intensity units/ml, p = 0.002]. Compared with those with a FLOP level below the 75th percentile, participants with a FLOP level above the 75th percentile had increased odds of CKD after adjustment for covariables (FLOP1: odds ratio 13.1, 95% confidence interval 6.2-27.6; FLOP2: odds ratio 5.7, 95% confidence interval 2.9-11.1; FLOP3: odds ratio 2.4, 95% confidence interval 1.2-4.7). Levels of FLOP1, FLOP2 and FLOP3 were related to eGFR (p < 0.0001 for all) and log-transformed urine albumin (p < 0.005 for all) in multivariable-adjusted linear regression models. CONCLUSION: These data indicate that an elevated FLOP level is associated with CKD status and severity. Future studies are warranted to elucidate its role in the development and progression of CKD.
Authors: Mattias Carlström; En Yin Lai; Zufu Ma; Andreas Steege; Andreas Patzak; Ulf J Eriksson; Jon O Lundberg; Christopher S Wilcox; A Erik G Persson Journal: Hypertension Date: 2010-09-27 Impact factor: 10.190
Authors: M Boaz; S Smetana; T Weinstein; Z Matas; U Gafter; A Iaina; A Knecht; Y Weissgarten; D Brunner; M Fainaru; M S Green Journal: Lancet Date: 2000-10-07 Impact factor: 79.321
Authors: A Mezzetti; G Zuliani; F Romano; F Costantini; S D Pierdomenico; F Cuccurullo; R Fellin Journal: J Am Geriatr Soc Date: 2001-05 Impact factor: 5.562
Authors: Brenda R Hemmelgarn; Braden J Manns; Anita Lloyd; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Marcello Tonelli Journal: JAMA Date: 2010-02-03 Impact factor: 56.272
Authors: B Payson Oberg; Elizabeth McMenamin; F Lee Lucas; Ellen McMonagle; Jason Morrow; T Alp Ikizler; Jonathan Himmelfarb Journal: Kidney Int Date: 2004-03 Impact factor: 10.612
Authors: Z Makita; S Radoff; E J Rayfield; Z Yang; E Skolnik; V Delaney; E A Friedman; A Cerami; H Vlassara Journal: N Engl J Med Date: 1991-09-19 Impact factor: 91.245
Authors: Tianying Wu; Nader Rifai; L Jackson Roberts; Walter C Willett; Eric B Rimm Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-08 Impact factor: 4.254
Authors: Francis B Annor; Michael Goodman; Ike S Okosun; Douglas W Wilmot; Dora Il'yasova; Murugi Ndirangu; Sindhu Lakkur Journal: J Am Soc Hypertens Date: 2015-06-05
Authors: Jing Chen; L Lee Hamm; Joshua D Bundy; Damodar R Kumbala; Shirisha Bodana; Sehgal Chandra; Chung-Shiuan Chen; Charlton C Starcke; Yajun Guo; Caroline M Schaefer; Eva Lustigova; Erin Mahone; Aarti M Vadalia; Terra Livingston; Katherine Obst; Jesus Hernandez; Syed Rizwan Bokhari; Myra Kleinpeter; Arnold B Alper; Ivo Lukitsch; Hua He; David C Nieman; Jiang He Journal: Clin J Am Soc Nephrol Date: 2020-10-06 Impact factor: 8.237
Authors: Luenda E Charles; Ja K Gu; Desta Fekedulegn; Michael E Andrew; John M Violanti; Cecil M Burchfiel Journal: J Occup Environ Med Date: 2013-11 Impact factor: 2.162
Authors: Majken K Jensen; Yushan Wang; Eric B Rimm; Mary K Townsend; Walter Willett; Tianying Wu Journal: J Am Heart Assoc Date: 2013-10-08 Impact factor: 5.501